Navigation Links
BU presents approach to access biorelevant structures by 'remodeling' natural products
Date:10/24/2011

There is an increasing need for pharmacological tools for biomedical and translational research applications. The field of diversity-oriented synthesis (DOS) has been very fruitful in providing access to numerous new molecules with diverse shapes and chemical structures in order to discover candidate molecules for therapeutic use. Boston University researchers, in a paper published in the journal Nature Chemistry [23 OCTOBER 2011 | DOI: 10.1038/NCHEM.1178], present a new approach to accessing new, biorelevant structures by "remodelling" natural products. In this case, they demonstrate how the natural product derivative fumagillol can been remodelled to access a collection of new molecules using highly efficient chemical reactions.

"Overall, these studies should pave the way for work to identify pharmacological tools for use in CNS research, oncology, and as anti-infective agents," said John A. Porco, Jr., professor of chemistry at Boston University. "These studies also will enable future studies to remodel additional natural product scaffolds to access novel therapeutic agents."

In the search for novel biologically active molecules, DOS strategies break through the limitation of traditional library synthesis by sampling new chemical space. Many natural products can be regarded as useful starting points for DOS, wherein stereochemically rich core structures may be reorganized into chemotypes that are distinctly different from the parent structure. Ideally, to be suited to library applications, such transformations should be general and involve few steps.

With this objective in mind, Porco and colleagues including Professor John Snyder and postdoctoral fellow Dr. Brad Balthaser successfully remodelled the highly oxygenated natural product fumagillol in several ways using a reaction-discovery-based approach. In reactions with amines, excellent selectivity in a bis-epoxide opening/cyclization sequence was obtained using the appropriate metals catalysts forming either perhydroisoindole or perhydroisoquinoline products. Perhydroisoindoles were further remodelled to other complex structures including novel benzoxazepines.


'/>"/>

Contact: Patrick Farrell
pmfarrel@bu.edu
617-358-1185
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. FAB-HOMES™ Presents First Passive House Collection
2. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
3. AADR presents honorary membership to Senator Tom Harkin
4. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
5. Refine Dermatique Aesthetic Medical Team Presents Free Educational Event in Otsego, MN
6. CNBC Presents 'Tom Brokaw Reports: BOOMER$!' on Thursday, March 4th at 9PM ET/PT
7. Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership
8. CareTech Solutions Presents Specialized Healthcare Call Center at HIMSS10
9. Morehead Presents Webinar on "When Satisfaction Isn't Enough: Improving RN Engagement"
10. Targeting leukemia cells gene addiction presents new strategy for treatment
11. Keynote Speaker Presents Top Business Plan For Internal Communication Through Social Media
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... May 2016 – Lips ... central to popular cosmetic improvement efforts. Record numbers of clients now ask about lip ... or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , The ...
(Date:5/26/2016)... ... May 26, 2016 , ... In 1980, Bill Howe ... calls throughout the beach community. His vision to grow the company was built on ... they maintain the highest level of training and customer service. Over 35 years later, ...
(Date:5/26/2016)... SAN DIEGO, California (PRWEB) , ... May 26, ... ... to Santa Barbara this Memorial Day weekend to host their second pop-up shop ... the San Diego fashion forward brand to the Santa Barbara community, a community ...
(Date:5/25/2016)... Francisco, CA (PRWEB) , ... May 26, 2016 , ... ... 2016, from 6pm to 7.30pm PST at HP in Palo Alto, CA. This Bay ... discussion will be led by clinical trial experts from the pharmaceutical company Hallux, biopharma ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Furthering its position ... athletics, The National Center for Drug Free Sport (Drug Free Sport®) is excited to ... conference, to be held July 12 – 13 in Kansas City, MO, will gather ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 According ... by Type (3D, 2D, 4D), by Therapeutic Area (Oncology, ... End User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast ... global Medical Animation Market for the forecast period of ... USD 301.3 Million by 2021 from USD 117.3 Million ...
(Date:5/25/2016)... 2016  According to Kalorama Information, the world ... 2015.  Though these are challenging times in the ... success for companies that remain optimistic and seek ... growth prospects medical device companies spend a higher ... (R&D) than do companies in other industries.  Also, ...
(Date:5/25/2016)... 25, 2016 Digital Health Dialog, LLC ... by the US Patent and Trademark Office of ... proprietary processes for electronic opt-­in and processing of ... programs, HIPAA compliance and otherwise. Logo - ... "Our technology allows for individuals to ...
Breaking Medicine Technology: